Project Grant P50HD117373
Award Date
8/15/24
Completion Date
7/31/28
Dollars Obligated
$1.6M
Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $525,048 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Children's Hospital Medical Center in Cincinnati, OH. The grant is titled "Development and Optimization of Skeletal Muscle Delivery Vehicles" and runs from July 8, 2024 to May 31, 2029. The project aims to develop novel gene therapy delivery vehicles, including lentiviruses and extracellular vesicles,...
This federal Project Grant award of $692,292.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to understand the regulation of pediatric skeletal muscle regeneration and its implications for treating muscle diseases such as Duchenne muscular dystrophy (DMD). The research aims to examine the role of the muscle niche, including immune and...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop improved gene replacement and editing vectors for the treatment of Duchenne muscular dystrophy (DMD). The $671,240 award will fund research at the University of Washington over a 5-year period from January 2025 to December 2029. The key objectives are to: 1) Refine technologies...
This Project Grant award of $2,123,500.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) aims to develop a novel gene therapy approach to treat muscular dystrophies. The key products and services to be delivered under this grant include: Demonstrating the feasibility of using a dual adeno-associated viral (AAV) vector system to deliver full-length dysferlin, a protein deficient in...
The Department of the Army's Military Medical Research and Development (CFDA 12.420) federal grant program has awarded a $777,659 Project Grant to the Children's Research Institute (a non-profit hospital and research organization) to support "USE OF PRORESOLUTION AND RESTORATIVE PHARMACOLOGY APPROACHES FOR DMD THERAPY". This award, effective from August 1, 2025 to July 31, 2028, will fund advanced biomedical research focused on transforming healthcare for military service members and...
This is a $538,218 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by the University of Texas Health Science Center at Houston (UTHealth) to study the role of ERR-alpha in skeletal muscle regeneration and functional recovery for Duchenne muscular dystrophy. The project aims to advance scientific understanding and develop potential treatments for this debilitating...
This $1,464,751 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, Los Angeles (UCLA) to develop adeno-associated virus (AAV) vectors targeted to muscle and muscle stem cells. The goal is to improve the therapeutic efficacy and safety of treatments for Duchenne muscular dystrophy. The award period runs from September 1, 2024 to August 31, 2027. As the prime awardee, UCLA...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
The Department of the Army Medical Command awarded a $405,341 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program to the Children's Research Institute, located in Washington, D.C. The grant, which runs from August 1, 2025 to July 31, 2028, supports the use of pro-resolution and restorative pharmacology approaches for developing a new therapy for Duchenne muscular dystrophy (DMD). As a leading pediatric research organization, the Children's...
This $661,501 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for the period of September 1, 2024 through August 31, 2027. The award will fund research to develop AAV (adeno-associated virus) vectors targeted to muscle and muscle stem cells, which offer improved therapeutic efficacy and safety for treating Duchenne muscular dystrophy. UCLA, through...